98%
921
2 minutes
20
Background: In a retrospective multicentre cohort study, we explored the association between brain atrophy and multiple sclerosis (MS) disability using different MRI scanners and protocols at multiple sites.
Methods: Relapse-onset MS patients were included if they had two clinical MRIs 12 months apart and ≥2 Expanded Disability Status Scale (EDSS) scores. Percentage brain volume change (PBVC), percentage grey matter change (PGMC), fluid-attenuated inversion recovery (FLAIR) lesion volume change, whole brain volume (BV), grey matter volume (GMV), FLAIR lesion volume and T1 hypointense lesion volume were assessed by icobrain. Disability was measured by EDSS scores and 6-month confirmed disability progression (CDP).
Results: Of the 260 relapse-onset MS patients included, 204 (78%) MRI pairs were performed in the same scanner and 56 (22%) pairs were from different scanners. 93% of patients were on treatment and mean PBVC was -0.26% (±0.52). During the median follow-up of 2.8 years from the second MRI, median EDSS change was 0.0 and 12% patients experienced 6-month CDP. Cross-sectional BV and GMV at the later MRI showed a trend for association with CDP (HR 0.99; 95% CI 0.98 to 1.00; p=0.06). Only BV at the later MRI was associated with EDSS score (β -0.03, SE 0.01, p<0.001) and the rate of EDSS change over time (β -0.001, SE 0.0003, p=0.02). There was no association between longitudinal PBVC or PGMC and CDP or EDSS (p>0.05).
Conclusion: In this highly treated MS cohort with low disability accrual, only cross-sectional BV showed an association with future EDSS scores, while no MRI metric predicted 6-month CDP. These findings highlight the limitations of current clinical MRI measures in predicting disability worsening in real-world settings.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306358 | PMC |
http://dx.doi.org/10.1136/bmjno-2025-001126 | DOI Listing |
J Neurol Neurosurg Psychiatry
September 2025
Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.
Background: Autologous haematopoietic stem cell transplantation (AHSCT) is increasingly used as a one-off disease-modifying therapy for aggressive forms of multiple sclerosis (MS). We report real-world effectiveness of AHSCT for MS in the UK.
Methods: This retrospective open-label study included patients with (pw)MS treated with AHSCT between 2002 and 2023 in 14 UK centres.
Brain Commun
August 2025
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.
Patients with relapsing-remitting multiple sclerosis (RRMS) may experience disability progression independent of relapse activity (PIRA), which can be an early sign of secondary progressive MS (SPMS). We defined persistent PIRA as ongoing sustained disability over the entire available follow-up period. However, PIRA events can regress over time.
View Article and Find Full Text PDFClin Chim Acta
September 2025
Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University, No. 119, South Fourth Ring West Road, Fengtai District, Beijing 100070, People's Republic of China; NMPA, Key Laboratory for Quality Control of In Vitro Diagnostics, No. 119 South Fourth Ring West Road, Fengtai Distri
Background: G protein-coupled receptor 37 (GPR37) has recently been earmarked as a rising candidate for use as a marker for central nervous system (CNS) demyelinating illness. In this study, we explored the ability of serum GPR37 to assess disease activity, functional impairment, and the efficacy of therapeutic interventions in patient cases of neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS).
Methods: We prospectively enrolled 144 cases of NMOSD and 132 cases of MS, as well as 160 controls (healthy individuals and cases of other neural disorders).
Mult Scler Relat Disord
August 2025
Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:
Introduction: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system, leading to neurodegeneration and disability. Mesenchymal stem cell (MSC) therapy has emerged as a promising approach due to its immunomodulatory and neuroprotective properties.
Objective: This systematic review aims to evaluate the therapeutic potential of mesenchymal stem cell (MSC) therapy in the treatment of multiple sclerosis (MS).
Mol Ther
September 2025
Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China. Electronic address:
Neuromyelitis Optica spectrum disorder (NMOSD) is a relapsing autoimmune disease primarily affecting the optic nerves and spinal cord. While the pathogenesis of NMO involves Aquaporin-4 antibodies (AQP4-IgG) and complement-mediated damage, the specific roles of the complement pathway remain to be fully elucidated. In this study, we found that complement factor H-related protein 2 (CFHR2), a regulator that inhibits the complement C3 alternative pathway, was significantly decreased in the serum of NMO patients and was negatively correlated with the Expanded Disability Status Scale (EDSS) score.
View Article and Find Full Text PDF